
NUTX Stock Forecast & Price Target
NUTX Analyst Ratings
Bulls say
Nutex Health Inc reported revenue of $7.8 million in the first quarter, marking a 5.4% year-over-year increase, which indicates a steady growth trajectory. The company's patient revenue per visit improved significantly, by 37% year-over-year and 17% quarter-over-quarter, reflecting enhancements in negotiated rates and increased patient acuity. Additionally, the gross margin expanded to 56% compared to 15% in the previous year, supported by controlled general and administrative expenses that rose only 15% year-over-year, further underscoring the company's operational efficiency and profitability potential.
Bears say
Nutex Health experienced a significant decline in arbitration-related revenue in the first quarter, falling to $105 million from $142 million in the previous quarter, which raises concerns about the sustainability of its revenue sources. Additionally, the diluted earnings per share (EPS) dropped drastically from $11.12 in the previous quarter to $2.56, indicating potential challenges in maintaining profitability despite a year-over-year improvement from negative earnings. Although segment operating income increased to $109 million, or 53% of revenue, the volatility in revenue streams and declining EPS suggest underlying issues that could negatively impact the company's future financial performance.
This aggregate rating is based on analysts' research of Nutex Health Inc and is not a guaranteed prediction by Public.com or investment advice.
NUTX Analyst Forecast & Price Prediction
Start investing in NUTX
Order type
Buy in
Order amount
Est. shares
0 shares